Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.

Lale Erdem-Eraslan, Martin J. van den Bent, Youri Hoogstrate, Hina Naz-Khan, Andrew Stubbs, Peter van der Spek, René Böttcher, Ya Gao, Maurice de Wit, Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp, Laurens V. Beerepoot, Monique C.J. Hanse, Jan Buter, Aafke H. Honkoop, Bronno van der Holt, René M. Vernhout, Peter A.E. Sillevis Smitt, Johan M. Kros, Pim J. French, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy : A Report from the BELOB Trial Cancer Research. ,vol. 76, pp. 525- 534 ,(2016) , 10.1158/0008-5472.CAN-15-0776

Thomas Urup, Rikke Hedegaard Dahlrot, Kirsten Grunnet, Ib Jarle Christensen, Signe Regner Michaelsen, Anders Toft, Vibeke Andrée Larsen, Helle Broholm, Michael Kosteljanetz, Steinbjørn Hansen, Hans Skovgaard Poulsen, Ulrik Lassen, Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan Acta Oncologica. ,vol. 55, pp. 418- 422 ,(2016) , 10.3109/0284186X.2015.1114679

Katharina Seystahl, Wolfgang Wick, Michael Weller, Therapeutic options in recurrent glioblastoma--An update. Critical Reviews in Oncology Hematology. ,vol. 99, pp. 389- 408 ,(2016) , 10.1016/J.CRITREVONC.2016.01.018

B Campos, L R Olsen, T Urup, H S Poulsen, A comprehensive profile of recurrent glioblastoma Oncogene. ,vol. 35, pp. 5819- 5825 ,(2016) , 10.1038/ONC.2016.85

Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Lassen, Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients Molecular Oncology. ,vol. 10, pp. 1160- 1168 ,(2016) , 10.1016/J.MOLONC.2016.05.005

Wolfgang Wick, Alba Ariela Brandes, Thierry Gorlia, Martin Bendszus, Felix Sahm, Walter Taal, Martin J.B. Taphoorn, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M. Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, François Dubois, Martin Klein, Michael Platten, Michael Weller, Vassilis Golfinopoulos, Martin J. Van Den Bent, EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. Journal of Clinical Oncology. ,vol. 34, pp. 2001- 2001 ,(2016) , 10.1200/JCO.2016.34.15_SUPPL.2001

Hans Skovgaard Poulsen, Kirsten Grunnet, Morten Sorensen, Preben Olsen, Benedikte Hasselbalch, Knud Nelausen, Michael Kosteljanetz, Ulrik Lassen, Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours Acta Oncologica. ,vol. 48, pp. 52- 58 ,(2009) , 10.1080/02841860802537924

S Møller, K Grunnet, S Hansen, H Schultz, M Holmberg, HS Sorensen, M, Poulsen, U Lassen, A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy Acta Oncologica. ,vol. 51, pp. 797- 804 ,(2012) , 10.3109/0284186X.2012.681063

Balveen Kaur, Fatima W. Khwaja, Eric A. Severson, Shannon L. Matheny, Daniel J. Brat, Erwin G. Van Meir, Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis Neuro-oncology. ,vol. 7, pp. 134- 153 ,(2005) , 10.1215/S1152851704001115

Julien Laffaire, Anna Luisa Di Stefano, Olivier Chinot, Ahmed Idbaih, Jaime Gallego Perez-Larraya, Yannick Marie, Nadia Vintonenko, Blandine Boisselier, Patrizia Farina, Jean-Yves Delattre, Dominique Figarella-Branger, Jérôme Honnorat, Marc Sanson, François Ducray, An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas BioMed Research International. ,vol. 2014, pp. 282815- 282815 ,(2014) , 10.1155/2014/282815